drugset / Trial / NCT05059327

Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

NCT05059327

Phase 2 Completed 61 enrolled Noema Pharma AG
RandomizedCrossoverDouble-blindTreatment

Summary

The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).

Timeline

Start
2022-03-03
Primary completion
2025-02-06
Completion
2025-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Basimglurant Small molecule

Indications